{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:02:01Z","timestamp":1792929721048,"version":"4.5.0"},"reference-count":65,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T00:00:00Z","timestamp":1720915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Emerging evidence has shown remarkable advances in the multimodal treatment of esophageal squamous-cell carcinoma. Despite these advances, the oncological outcomes for advanced esophageal cancer remain controversial due to the frequent observation of local recurrence in the regional or other lymph nodes and distant metastasis after curative treatment. For cases of locoregional recurrence in the cervical lymph nodes alone, salvage surgery with lymph node dissection generally provides a good prognosis. However, if recurrence occurs in multiple regions, the oncological efficacy of surgery may be limited. Radiotherapy\/chemoradiotherapy can be employed for unresectable or recurrent cases, as well as for selected cases in neo- or adjuvant settings. Dose escalation and toxicity are potential issues with conventional three-dimensional conformal radiotherapy; however, more precise therapeutic efficacy can be obtained using technical modifications with improved targeting and conformality, or with the use of proton beam therapy. The introduction of immune checkpoint inhibitors, including pembrolizumab or nivolumab, in addition to chemotherapy, has been shown to improve the overall survival in unresectable, advanced\/recurrent cases. For patients with lymph node recurrence in multiple regions, chemotherapy (5-fluorouracil [5-FU] plus cisplatin) and combination therapy with nivolumab and ipilimumab have shown comparable oncological efficacy. Further prospective studies are needed to improve the treatment outcomes in patients with esophageal cancer with locoregional recurrence.<\/jats:p>","DOI":"10.3390\/cancers16142539","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T08:35:17Z","timestamp":1721032517000},"page":"2539","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Treatment Strategies for Locoregional Recurrence in Esophageal Squamous-Cell Carcinoma: An Updated Review"],"prefix":"10.3390","volume":"16","author":[{"given":"Atsushi","family":"Mitamura","sequence":"first","affiliation":[{"name":"Division of Gastroenterological Surgery, Department of Surgery, Tohoku Medical and Pharmaceutical University, Sendai 983-8536, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8554-3869","authenticated-orcid":false,"given":"Shingo","family":"Tsujinaka","sequence":"additional","affiliation":[{"name":"Division of Gastroenterological Surgery, Department of Surgery, Tohoku Medical and Pharmaceutical University, Sendai 983-8536, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Nakano","sequence":"additional","affiliation":[{"name":"Division of Gastroenterological Surgery, Department of Surgery, Tohoku Medical and Pharmaceutical University, Sendai 983-8536, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Sawada","sequence":"additional","affiliation":[{"name":"Division of Gastroenterological Surgery, Department of Surgery, Tohoku Medical and Pharmaceutical University, Sendai 983-8536, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikashi","family":"Shibata","sequence":"additional","affiliation":[{"name":"Division of Gastroenterological Surgery, Department of Surgery, Tohoku Medical and Pharmaceutical University, Sendai 983-8536, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.21037\/acs.2017.03.14","article-title":"8th edition AJCC\/UICC staging of cancers of the esophagus and esophagogastric junction: Application to clinical practice","volume":"6","author":"Rice","year":"2017","journal-title":"Ann. Cardiothorac. Surg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10388-024-01054-y","article-title":"Japanese Classification of Esophageal Cancer, 12th Edition: Part I","volume":"21","author":"Mine","year":"2024","journal-title":"Esophagus"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10388-023-00993-2","article-title":"Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: Part 1","volume":"20","author":"Kitagawa","year":"2023","journal-title":"Esophagus"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10388-023-00994-1","article-title":"Esophageal cancer practice guidelines 2022 edited by the Japan Esophageal Society: Part 2","volume":"20","author":"Kitagawa","year":"2023","journal-title":"Esophagus"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/SLA.0000000000005782","article-title":"Robotic Versus Conventional Minimally Invasive Esophagectomy for Esophageal Cancer: A Meta-analysis","volume":"278","author":"Zhang","year":"2023","journal-title":"Ann. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1245\/s10434-011-2049-9","article-title":"A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907)","volume":"19","author":"Ando","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/jjco\/hyt061","article-title":"Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study)","volume":"43","author":"Nakamura","year":"2013","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1200\/JCO.2022.40.4_suppl.238","article-title":"A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study","volume":"40","author":"Kato","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10388-022-00950-5","article-title":"Comprehensive registry of esophageal cancer in Japan, 2015","volume":"20","author":"Watanabe","year":"2023","journal-title":"Esophagus"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1200\/JCO.2013.51.2186","article-title":"Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials","volume":"32","author":"Oppedijk","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): Long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/1749-8090-8-215","article-title":"Recurrence risk after Ivor Lewis oesophagectomy for cancer","volume":"8","author":"Filleron","year":"2013","journal-title":"J. Cardiothorac. Surg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/dote\/dox082","article-title":"Treatment strategies in recurrent esophageal or junctional cancer","volume":"30","author":"Butter","year":"2017","journal-title":"Dis. Esophagus"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Hagens, E.R.C., van Berge Henegouwen, M.I., and Gisbertz, S.S. (2020). Distribution of Lymph Node Metastases in Esophageal Carcinoma Patients Undergoing Upfront Surgery: A Systematic Review. Cancers, 12.","DOI":"10.3390\/cancers12061592"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1245\/s10434-011-1747-7","article-title":"Survival factors in patients with recurrence after curative resection of esophageal squamous cell carcinomas","volume":"18","author":"Miyata","year":"2011","journal-title":"Ann. Surg. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s11605-011-1458-1","article-title":"Prognostic factors for post-recurrence survival in esophageal squamous cell carcinoma patients with recurrence after resection","volume":"15","author":"Hsu","year":"2011","journal-title":"J. Gastrointest. Surg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10388-009-0221-0","article-title":"Follow-up and recurrence after a curative esophagectomy for patients with esophageal cancer: The first indicators for recurrence and their prognostic values","volume":"7","author":"Toh","year":"2010","journal-title":"Esophagus"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1007\/s11605-007-0385-7","article-title":"Surgical outcomes in esophageal cancer patients with tumor recurrence after curative esophagectomy","volume":"12","author":"Kunisaki","year":"2008","journal-title":"J. Gastrointest. Surg."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1007\/s00595-012-0133-9","article-title":"Patterns and time of recurrence after complete resection of esophageal cancer","volume":"42","author":"Sugiyama","year":"2012","journal-title":"Surg. Today"},{"key":"ref_21","first-page":"3461","article-title":"Classification of recurrent esophageal cancer after radical esophagectomy with two- or three-field lymphadenectomy","volume":"25","author":"Kato","year":"2005","journal-title":"Anticancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jamcollsurg.2010.01.006","article-title":"Recurrence after esophagectomy for adenocarcinoma: Defining optimal follow-up intervals and testing","volume":"210","author":"Abate","year":"2010","journal-title":"J. Am. Coll. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1245\/s10434-014-4008-8","article-title":"Salvage lymphadenectomy versus salvage radiotherapy\/chemoradiotherapy for recurrence in cervical lymph node after curative resection of esophageal squamous cell carcinoma","volume":"22","author":"Ma","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1245\/s10434-008-0016-x","article-title":"Multimodal treatment for lymph node recurrence of esophageal carcinoma after curative resection","volume":"15","author":"Nakamura","year":"2008","journal-title":"Ann. Surg. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s11748-014-0444-4","article-title":"Outcomes of lymphadenectomy for lymph node recurrence after esophagectomy or definitive chemoradiotherapy for squamous cell carcinoma of the esophagus","volume":"62","author":"Watanabe","year":"2014","journal-title":"Gen. Thorac. Cardiovasc. Surg."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1442-2050.2011.01215.x","article-title":"Salvage lymphadenectomy for cervical lymph node recurrence after esophagectomy for squamous cell carcinoma of the thoracic esophagus","volume":"25","author":"Watanabe","year":"2012","journal-title":"Dis. Esophagus"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Shigeno, T., Hoshino, A., Matsunaga, S., Shimano, R., Ishibashi, N., Shinohara, H., Shiobara, H., Tomii, C., Saito, K., and Fujiwara, N. (2022). The impact of lymphadenectomy on lymph node recurrence after performing various treatments for esophageal squamous cell carcinoma. BMC Surg., 22.","DOI":"10.1186\/s12893-022-01618-8"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann. Surg."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13014-017-0863-3","article-title":"Intensity-modulated versus 3-dimensional conformal radiotherapy in the definitive treatment of esophageal cancer: Comparison of outcomes and acute toxicity","volume":"12","author":"Haefner","year":"2017","journal-title":"Radiat. Oncol."},{"key":"ref_30","first-page":"1","article-title":"Comparison of three-dimensional conformal radiation therapy, intensity-modulated radiation therapy, and volumetric-modulated arc therapy in the treatment of cervical esophageal carcinoma","volume":"30","author":"Yang","year":"2017","journal-title":"Dis. Esophagus"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/dote.12203","article-title":"Comparative outcomes for three-dimensional conformal versus intensity-modulated radiation therapy for esophageal cancer","volume":"28","author":"Freilich","year":"2015","journal-title":"Dis. Esophagus"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"Hulshof","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13014-023-02265-w","article-title":"Re-irradiation for local primary-recurrence esophageal squamous cell carcinoma treated with IMRT\/VMAT","volume":"18","author":"Xiang","year":"2023","journal-title":"Radiat. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13014-019-1377-y","article-title":"Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma","volume":"14","author":"Chen","year":"2019","journal-title":"Radiat. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13014-017-0780-5","article-title":"Definitive salvage radiation therapy and chemoradiation therapy for lymph node oligo-recurrence of esophageal cancer: A Japanese multi-institutional study of 237 patients","volume":"12","author":"Yamashita","year":"2017","journal-title":"Radiat. Oncol."},{"key":"ref_36","first-page":"1","article-title":"Isolated local recurrence or solitary solid organ metastasis after esophagectomy for cancer is not the end of the road","volume":"30","author":"Depypere","year":"2017","journal-title":"Dis. Esophagus"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3857\/roj.2012.30.4.182","article-title":"Re-irradiation of recurrent esophageal cancer after primary definitive radiotherapy","volume":"30","author":"Kim","year":"2012","journal-title":"Radiat. Oncol. J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"20200183","DOI":"10.1259\/bjr.20200183","article-title":"Particle therapy in the future of precision therapy","volume":"93","author":"Schaub","year":"2020","journal-title":"Br. J. Radiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.21873\/invivo.13202","article-title":"Clinical Impact of Proton Beam Therapy for Postoperative Lymph Node Oligorecurrence of Esophageal Cancer","volume":"37","author":"Hiroshima","year":"2023","journal-title":"In Vivo"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Solidum, J.G.N., Rojo, R.D., Wo, J.Y., and Dee, E.C. (2022). Proton Beam Therapy for Esophageal Cancer. Cancers, 14.","DOI":"10.3390\/cancers14164045"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"79","DOI":"10.21037\/atm.2017.11.28","article-title":"Advances in radiotherapy for esophageal cancer","volume":"6","author":"Deng","year":"2018","journal-title":"Ann. Transl. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.rpor.2020.02.005","article-title":"Cardiotoxicity of radiation therapy in esophageal cancer","volume":"25","author":"Hodek","year":"2020","journal-title":"Rep. Pract. Oncol. Radiother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.ijrobp.2009.06.091","article-title":"Radiation dose-volume effects in the lung","volume":"76","author":"Marks","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ijrobp.2013.07.008","article-title":"Symptomatic pericardial effusion after chemoradiation therapy in esophageal cancer patients","volume":"87","author":"Fukada","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.ijrobp.2009.04.093","article-title":"Radiation dose-volume effects in the heart","volume":"76","author":"Gagliardi","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s10388-024-01048-w","article-title":"Japanese Classification of Esophageal Cancer, 12th Edition: Part II","volume":"21","author":"Doki","year":"2024","journal-title":"Esophagus"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/S0959-8049(97)00088-9","article-title":"Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer","volume":"33","author":"Bleiberg","year":"1997","journal-title":"Eur. J. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Lee, S.J., Kim, S., Kim, M., Lee, J., Park, Y.H., Im, Y.H., and Park, S.H. (2015). Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: A randomized phase II study. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1716-9"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/annonc\/mdp069","article-title":"Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: A randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie","volume":"20","author":"Lorenzen","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.annonc.2019.10.018","article-title":"Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: A prospective, open-label, randomised phase III AIO\/EORTC trial (POWER)","volume":"31","author":"Moehler","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1634\/theoncologist.2018-0143","article-title":"Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma","volume":"23","author":"Salem","year":"2018","journal-title":"Oncologist"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","article-title":"Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): A multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Kato","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10388-022-00970-1","article-title":"First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: A Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648\/ONO-4538-50)","volume":"20","author":"Kato","year":"2023","journal-title":"Esophagus"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1200\/JCO.20.01888","article-title":"Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer","volume":"38","author":"Kojima","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): A randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of Camrelizumab vs. Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial","volume":"326","author":"Luo","year":"2021","journal-title":"JAMA"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ccell.2022.02.007","article-title":"Toripalimab plus chemotherapy in treatment-na\u00efve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial","volume":"40","author":"Wang","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e068714","DOI":"10.1136\/bmj-2021-068714","article-title":"Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): Multicentre, randomised, double blind, phase 3 trial","volume":"377","author":"Lu","year":"2022","journal-title":"BMJ"},{"key":"ref_63","first-page":"1765","article-title":"A Case of Unresectable Advanced Lower Esophageal Adenocarcinoma That Achieved Pathological Complete Response after Conversion Surgery following Nivolumab plus SOX Therapy","volume":"50","author":"Yamamichi","year":"2023","journal-title":"Gan Kagaku Ryoho"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Sato, Y., Tanaka, Y., Yokoi, R., Tsuchiya, H., Sengoku, Y., Fukada, M., Yasufuku, I., Asai, R., Tajima, J.Y., and Kiyama, S. (2024). Oligometastases of Esophageal Squamous Cell Carcinoma: A Review. Cancers, 16.","DOI":"10.3390\/cancers16040704"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/14\/2539\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:16:50Z","timestamp":1760109410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/14\/2539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,14]]},"references-count":65,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["cancers16142539"],"URL":"https:\/\/doi.org\/10.3390\/cancers16142539","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,14]]}}}